Build status - In Progress

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Peritoneal Metastases in Patients Undergoing Cytoreductive Surgery

Recruiting
18 years - 99 years
All
Phase 2
40 participants needed
1 Location

Brief description of study

This study involves metastatic, stage 4 cancer, that has spread to your abdominal cavity and your cancer surgeon recommends surgery to remove cancer tumors from your abdomen. The purpose of this research study is to learn if the investigational study drug, pegsitacianine, helps in seeing the metastatic cancer disease left behind following the standard of care cancer surgery to remove the metastatic tumors. This study will also help to learn about the safety of the study drug and the ability to see the metastatic cancer tumors of each person in the study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Peritoneal Carcinomatosis
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older Imaging and biopsy confirmed metastatic disease of peritoneal origin

Updated on 04 Aug 2024. Study ID: 850056

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center